Matthew Ros, See Remarks at Epizyme, Inc. (EPZM), sold 1,185 shares at $12.10 ($14K) on 2019-06-13, disclosed to the SEC on 2019-06-14.
Scheduled sale ($14k) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| EPZM | SELL | 2020-06-30 | $44K | — | Filing → |
| EPZM | SELL | 2020-06-22 | $4.7M | — | Filing → |
| EPZM | SELL | 2020-03-26 | $19K | — | Filing → |